FAKTOR OPTIONSSCHEIN - BOSTON SCIENTIFIC | Delayed Deutsche Boerse AG 10:35:23 2024-05-16 EDT | ||
| 170.2 EUR | +1.35% |
|
| Current month | +7.37% | ||
| 1 month | +26.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-05-16 | 170.2 | +1.35% |
| 24-05-15 | 167.9 | +3.16% |
| 24-05-14 | 162.8 | +2.04% |
| 24-05-13 | 159.5 | -3.54% |
| 24-05-10 | 165.4 | -1.94% |
Delayed Quote Deutsche Boerse AG
Last update May 16, 2024 at 10:35 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | 
BNP Paribas
|
| WKN | PC3BSX |
| ISIN | DE000PC3BSX4 |
| Date issued | 2022-11-04 |
| Strike | 74.45 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 173.4 € |
|---|---|
| Lowest since issue | 47.38 € |
| Spread | 1.1 € |
| Spread % | 0.64% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
74.45
USD
Average target price
81.33
USD
Spread / Average Target
+9.24%
- Stock Market
- Certificates
- Certificat